Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

Live Updates Live Coverage Updates appear automatically as they are published. Bull Case 10:16 am by Gerelyn Terzo JPMorgan ...

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a ...

Hims & Hers Health, a telehealth company, offers direct-to-patient platform to distribute prescription drugs and OTC ...

As voters head to the polls, the democratic socialist candidate appears to be neck-and-neck with Andrew Cuomo. That has many ...

It’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Scout Investments, Inc., an affiliate of Carillon Tower Advisers, released the “Carillon Scout Mid Cap Fund” first quarter ...

Novo Nordisk drops Hims & Hers because it was selling and promoting a cheaper copycat of Wegovy, its weight loss drug.

Stock markets have rallied after U.S. President Donald Trump announced a ceasefire in the Israel-Iran conflict, although the ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

U.S. stocks rallied, and the price of oil tumbled Monday on hopes that Iran will not disrupt the global flow of crude, ...